Related Experiment Video
Updated: May 29, 2026

Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis
1Division of Rheumatology, Allergy and Immunology, University of California, San Diego, School of Medicine, La Jolla, California 92093, USA.
Abstract:
Mitogen-activated protein kinase (MAPK) cascades are involved in inflammation and tissue destruction in rheumatoid arthritis (RA). In particular, c-Jun N-terminal kinase (JNK) is highly activated in RA fibroblast-like synoviocytes and synovium. However, defining the precise function of this kinase has been difficult because a selective JNK inhibitor has not been available. We now report the use of a novel selective JNK inhibitor and JNK knockout mice to determine the function of JNK in synoviocyte biology and inflammatory arthritis. The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes. Furthermore, AP-1 binding and collagenase mRNA accumulation were completely suppressed by SP600125. In contrast, complete inhibition of p38 had no effect, and ERK inhibition had only a modest effect. The essential role of JNK was confirmed in cultured synoviocytes from JNK1 knockout mice and JNK2 knockout mice, each of which had a partial defect in IL-1--induced AP-1 activation and collagenase-3 expression. Administration of SP600125 modestly decreased the rat paw swelling in rat adjuvant-induced arthritis. More striking was the near-complete inhibition of radiographic damage that was associated with decreased AP-1 activity and collagenase-3 gene expression. Therefore, JNK is a critical MAPK pathway for IL-1--induced collagenase gene expression in synoviocytes and in joint arthritis, indicating that JNK is an important therapeutic target for RA.
Insights
A novel selective inhibitor of c-Jun N-terminal kinase (JNK) and JNK knockout mice reveal JNK
Area of Science:
- Molecular Biology
- Immunology
- Rheumatology
Background:
- Mitogen-activated protein kinase (MAPK) pathways, including c-Jun N-terminal kinase (JNK), are implicated in rheumatoid arthritis (RA) pathogenesis.
- JNK is highly activated in RA fibroblast-like synoviocytes and synovium, but its precise role has been unclear due to the lack of selective inhibitors.
Purpose of the Study:
- To elucidate the function of JNK in synoviocyte biology and inflammatory arthritis using a novel selective JNK inhibitor and JNK knockout models.
Main Methods:
- Utilized the novel selective JNK inhibitor SP600125 and JNK1/JNK2 knockout mice.
- Assessed IL-1-induced activation of transcription factors (e.g., phospho-Jun, AP-1) and collagenase gene expression in synoviocytes.
- Evaluated the effects of SP600125 on paw swelling and radiographic damage in a rat adjuvant-induced arthritis model.
Main Results:
- SP600125 completely inhibited IL-1-induced phospho-Jun accumulation, c-Jun transcription, AP-1 binding, and collagenase mRNA in synoviocytes.
- JNK1 and JNK2 knockout synoviocytes showed partial defects in IL-1-induced AP-1 activation and collagenase-3 expression.
- SP600125 administration reduced paw swelling and significantly inhibited radiographic damage in a rat arthritis model.
Conclusions:
- JNK is a critical MAPK pathway mediating IL-1-induced collagenase gene expression in synoviocytes.
- Targeting JNK represents a promising therapeutic strategy for managing rheumatoid arthritis and its associated joint destruction.
Related Concept Videos
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
cAMP-dependent Protein Kinase Pathways
Role of Matrix Metalloproteases in Degradation of ECM
A...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

